23:09 , Feb 26, 2019 |  BC Extra  |  Company News

CytomX R&D day reveals Probody toxicity, chopped BMS deal

CytomX Therapeutics Inc. (NASDAQ:CTMX) lost $6.03 (32%) to $13.13 on Tuesday after reporting severe toxicity signals with its CD166 Probody-drug conjugate, and disclosing that partner Bristol-Myers Squibb Co. (NYSE:BMY) terminated three targets under their discovery...
03:20 , Feb 16, 2019 |  BioCentury  |  Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
21:43 , Jan 18, 2019 |  BioCentury  |  Product Development

ImmunoGen’s milestone year

Nearly three years after refocusing the company to boost long-term value creation, ImmunoGen Inc. expects 2019 to be the year the changes will begin to bear fruit, starting with Phase III data from its lead...
16:19 , Oct 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Publisher’s note: On Feb. 20, the authors of the Nature paper cited below retracted it due to issues with figure presentation and underlying data. Mouse studies suggest CAR T cells targeting ALCAM...
22:56 , Sep 5, 2018 |  BC Extra  |  Preclinical News

Two papers open door to T cell brain entry for glioblastoma therapy

Publisher’s note: On Feb. 20, the authors of the Nature paper cited below retracted it due to issues with figure presentation and underlying data. Two new studies have proposed solutions to different barriers that prevent...
18:32 , May 15, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Binding assays; cellular assays A click chemistry-based method for identifying cell surface glycoproteins that bind orphan ligands could help identify new therapeutic targets. The method involves three steps: mildly oxidizing live cells to produce...
18:10 , Mar 9, 2018 |  BC Week In Review  |  Company News

Pfizer ends PDC deal with CytomX

CytomX Therapeutics Inc. (NASDAQ:CTMX) disclosed in its 4Q17 earnings that it received notification that Pfizer Inc. (NYSE:PFE) plans to terminate a 2013 deal to develop and commercialize up to four Probody drug conjugate candidates using...
19:07 , Jul 3, 2017 |  BC Week In Review  |  Clinical News

CytomX begins Phase I/II of CX-2009 in solid tumors

CytomX Therapeutics Inc. (NASDAQ:CTMX) began the open-label, U.S. Phase I/II PROCLAIM-CX-2009 trial to evaluate CD166 PDC (CX-2009) in about 150 patients with metastatic or locally advanced unresectable solid tumors. The trial will recruit patients with...
18:15 , Feb 2, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Cell culture studies suggest inhibiting TPST2 , SLC35B2 or ALCAM could help treat HIV infection. Screening of a CRISPR library in an HIV-1-infected human CD4 + T cell line identified three...
08:00 , Nov 12, 2015 |  BC Innovations  |  Product R&D

Probodies, anticancer

Lauren Martz, Senior Writer  How successful checkpoint inhibitors and chimeric antigen receptor (CAR) T cells will be at revolutionizing oncology hangs largely on whether it will be possible to curb their on-target but off-tissue toxicities....